Objective Despite improved treatment, diabetes remains a chronic disease with major health risks and heavy burden on patients and society. Serious forms are caused by depletion in pancreatic beta cells and associated loss in insulin’s homeostatic control throughout life. Their cure requires restoration of a metabolically adequate beta cell mass. Implants of beta cell grafts prepared from human pancreases have shown proof-of-principle but also the need for developing a large-scale source for therapeutic cells. Our objective is to generate a functional beta cell mass by stem cell-derived implants in diabetes patients. A combined preclinical and clinical project will search recipient and implant conditions for formation and maturation of beta cells in subcutaneous implants of device-encapsulated pancreatic endodermal cells that are derived from human embryonic stem cells (hu-ES) and manufactured for clinical studies. We collected preclinical evidence for the therapeutic potential of this implant from comparison with clinically used human beta cell grafts. State-of-the art methods and markers have been developed to investigate the biology of implants and to monitor host immune and innate reactivity. This approach helps understand the basis for metabolic outcome and identify targets for improvement. Pilot studies examine the influence of the (auto)immune status of the patients. Data will determine transition to clinical efficacy studies, or indicate the need for further laboratory development. Implants in preclinical models will guide modifications in clinical protocols, and explore the biologic properties of grafts derived from human induced pluripotent stem cell (iPSc) as can also be prepared from diabetes patients. Our consortium joins innovating cells, methods, markers and minds in a unique combination of expert clinical, academic and industry activities that need each other to make progress in an ambitious program. Fields of science medical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesmedical biotechnologyimplants Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-15-2015 - Clinical research on regenerative medicine Call for proposal H2020-PHC-2014-2015 See other projects for this call Sub call H2020-PHC-2015-single-stage_RTD Funding Scheme RIA - Research and Innovation action Coordinator VRIJE UNIVERSITEIT BRUSSEL Net EU contribution € 3 400 000,00 Address Pleinlaan 2 1050 Bruxelles / brussel Belgium See on map Region Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Participants (6) Sort alphabetically Sort by Net EU contribution Expand all Collapse all VIACYTE, INC CORPORATION United States Net EU contribution € 1 000 000,00 Address General atomics court 3550 92121 San diego ca See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 OSPEDALE SAN RAFFAELE SRL Italy Net EU contribution € 600 000,00 Address Via olgettina 60 20132 Milano See on map Region Nord-Ovest Lombardia Milano Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 ACADEMISCH ZIEKENHUIS LEIDEN Netherlands Net EU contribution € 500 000,00 Address Albinusdreef 2 2333 ZA Leiden See on map Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 SOCIETE DES PRODUITS NESTLE SA Switzerland Net EU contribution € 0,00 Address Avenue nestle 55 1800 Vevey See on map Region Schweiz/Suisse/Svizzera Région lémanique Vaud Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 600 000,00 INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE France Net EU contribution € 100 000,00 Address Boulevard de l'hopital 47 75013 Paris See on map Region Ile-de-France Ile-de-France Paris Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 CENTER FOR BETA CELL THERAPY IN DIABETES Belgium Net EU contribution € 600 000,00 Address Laarbeeklaan 103 1090 Brussel See on map Region Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad Activity type Other Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
